Loading clinical trials...
Loading clinical trials...
A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Conditions
Interventions
Erlotinib
Hypofractionated Radiotherapy
Locations
2
United States
Northeast Radiation Oncology Center
Dunmore, Pennsylvania, United States
Thomas Jefferson Univeristy
Philadelphia, Pennsylvania, United States
Start Date
August 27, 2009
Primary Completion Date
December 1, 2012
Completion Date
December 1, 2012
Last Updated
April 30, 2025
NCT06855771
NCT06758401
NCT06120140
NCT04165798
NCT06667908
NCT06875310
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions